» Articles » PMID: 15699255

Retinoids and Pulmonary Hypertension

Overview
Journal Circulation
Date 2005 Feb 9
PMID 15699255
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Retinoic acid has antimitogenic effects on smooth muscle cells. Studies on the systemic circulation suggest that it may reduce vascular thickening. Relationships between retinoids and pulmonary hypertension/pulmonary vascular remodeling, however, have not been explored. Thus, the present study examined retinoid levels in plasma of patients with idiopathic pulmonary arterial hypertension and the effects of retinoic acid on human pulmonary artery smooth muscle cell growth.

Methods And Results: We measured retinoid levels by gas chromatograph-mass spectrometer technique in plasma of idiopathic pulmonary arterial hypertension patients and in age- and sex-matched healthy control subjects. Patients had significantly lower levels of all-trans retinoic acid and 13-cis retinoic acid than control subjects but similar 9-cis retinoic acid and retinol levels. In cultured human pulmonary artery smooth muscle cells, all-trans retinoic acid suppressed serotonin-induced cell growth. These cells were found to express the retinoid acid receptors RARalpha, RARbeta, RARgamma, RXRalpha, and RXRbeta. Gene array analysis showed that retinoic acid induces the expression of GADD45A, a known cell growth suppressor. Contrary to expectations, plasma from pulmonary hypertension patients suppressed cell growth, likely influenced by factors other than retinoids.

Conclusions: Idiopathic pulmonary arterial hypertension patients have reduced retinoic acid levels, and retinoic acid treatment can elicit growth-inhibitory signals in pulmonary artery smooth muscle cells in vitro. Thus, retinoic acid may influence pulmonary vascular remodeling in humans.

Citing Articles

Comprehensive analysis and validation of novel immune and vascular remodeling related genes signature associated with drug interactions in pulmonary arterial hypertension.

Wang J, Uddin M, Wang R, Gong Y, Wu Y Front Genet. 2022; 13:922213.

PMID: 36147486 PMC: 9486302. DOI: 10.3389/fgene.2022.922213.


A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Bryant A, Ebrahimi E, Nguyen A, Wolff C, Gumz M, Liu A Am J Physiol Lung Cell Mol Physiol. 2021; 322(1):L84-L101.

PMID: 34850650 PMC: 8759967. DOI: 10.1152/ajplung.00037.2021.


iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.

Gu M, Donato M, Guo M, Wary N, Miao Y, Mao S Sci Transl Med. 2021; 13(592).

PMID: 33952674 PMC: 8762958. DOI: 10.1126/scitranslmed.aba6480.


The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Woodcock C, Chan S J Cardiovasc Pharmacol Ther. 2019; 24(4):334-354.

PMID: 30773044 PMC: 6714051. DOI: 10.1177/1074248419829172.


Regulation of human airway smooth muscle cell migration and relevance to asthma.

Salter B, Pray C, Radford K, Martin J, Nair P Respir Res. 2017; 18(1):156.

PMID: 28814293 PMC: 5559796. DOI: 10.1186/s12931-017-0640-8.